226 related articles for article (PubMed ID: 25842974)
21. Stamina therapies: Let the record stand.
Bianco P; Cattaneo E; De Luca M; Pani L
Nature; 2014 Feb; 506(7489):434. PubMed ID: 24572414
[No Abstract] [Full Text] [Related]
22. Stem cell research and policy in India: current scenario and future perspective.
Sharma A
J Stem Cells; 2009; 4(2):133-40. PubMed ID: 20232598
[TBL] [Abstract][Full Text] [Related]
23. Accelerating regenerative medicine: the Japanese experiment in ethics and regulation.
Lysaght T
Regen Med; 2017 Sep; 12(6):657-668. PubMed ID: 28976822
[TBL] [Abstract][Full Text] [Related]
24. Health consumers and stem cell therapy innovation: markets, models and regulation.
Salter B; Zhou Y; Datta S
Regen Med; 2014 May; 9(3):353-66. PubMed ID: 24935045
[TBL] [Abstract][Full Text] [Related]
25. FDA challenges stem-cell clinic.
Cyranoski D
Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
[No Abstract] [Full Text] [Related]
26. Regulatory Frameworks for Gene and Cell Therapies in Japan.
Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
[TBL] [Abstract][Full Text] [Related]
27. Prospects for pluripotent stem cell therapies: into the clinic and back to the bench.
Grabel L
J Cell Biochem; 2012 Feb; 113(2):381-7. PubMed ID: 21928325
[TBL] [Abstract][Full Text] [Related]
28. The challenges of regulating stem cell-based products.
von Tigerstrom BJ
Trends Biotechnol; 2008 Dec; 26(12):653-8. PubMed ID: 18977047
[TBL] [Abstract][Full Text] [Related]
29. [Ethical, legal and social issues on regenerative medicine].
Tsukata Y
Nihon Geka Gakkai Zasshi; 2004 Aug; 105(8):435-9. PubMed ID: 15373219
[TBL] [Abstract][Full Text] [Related]
30. Global update: Japan.
Sipp D
Regen Med; 2011 Nov; 6(6 Suppl):160-2. PubMed ID: 21999281
[TBL] [Abstract][Full Text] [Related]
31. The government's role in advancing regenerative medicine and tissue engineering - science, safety, and ethics.
Smith DS
Periodontol 2000; 2006; 41():16-29. PubMed ID: 16686924
[No Abstract] [Full Text] [Related]
32. FDA's claims over stem cells upheld.
Cyranoski D
Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
[No Abstract] [Full Text] [Related]
33. 'Reprogrammed' stem cells approved to mend human hearts for the first time.
Cyranoski D
Nature; 2018 May; 557(7707):619-620. PubMed ID: 29844563
[No Abstract] [Full Text] [Related]
34. Regulatory perspectives of Japan.
Kusakabe T
Biologicals; 2015 Sep; 43(5):422-4. PubMed ID: 26028474
[TBL] [Abstract][Full Text] [Related]
35. The emergence and popularisation of autologous somatic cellular therapies in Australia: therapeutic innovation or regulatory failure?
McLean AK; Stewart C; Kerridge I
J Law Med; 2014 Sep; 22(1):65-89. PubMed ID: 25341320
[TBL] [Abstract][Full Text] [Related]
36. Stem Cells Transplantation in the Treatment of Patients with Liver Failure.
Tao YC; Wang ML; Chen EQ; Tang H
Curr Stem Cell Res Ther; 2018 Feb; 13(3):193-201. PubMed ID: 29303079
[TBL] [Abstract][Full Text] [Related]
37. Unproven stem cell interventions: A global public health problem requiring global deliberation.
Master Z; Matthews KRW; Abou-El-Enein M
Stem Cell Reports; 2021 Jun; 16(6):1435-1445. PubMed ID: 34107243
[TBL] [Abstract][Full Text] [Related]
38. Hope for regenerative treatments: toward safe transplantation of human pluripotent stem-cell-based therapies.
Kimbrel EA; Lanza R
Regen Med; 2015; 10(2):99-102. PubMed ID: 25835474
[No Abstract] [Full Text] [Related]
39. A Japanese Bioventure Company's Application of Stem Cell Technology in Regenerative Medicine.
Sawada M; Sugiyama D; Nii T; Konno K; Kagimoto HTS
Clin Ther; 2018 Nov; 40(11):1801-1806. PubMed ID: 30396514
[TBL] [Abstract][Full Text] [Related]
40. Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.
Qi SD; Smith PD; Choong PF
ANZ J Surg; 2014 Jun; 84(6):417-23. PubMed ID: 24894037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
